ADA Final Impressions
This year’s version of the annual ADA confab was like past year’s versions full of both hope and trepidation. The data especially for the coming crop of weight loss meds was very compelling. As we predicted long ago not only is CGM becoming the standard for glucose measurement the usage of CGM is moving into the non-diabetic consumer health arena. Yet even with these advancements in drugs and devices one indisputable fact remains the majority of patients are not achieving good control and nothing we saw at the show gives us much hope that will change anytime . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.